 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LABP-69 / Landos Biopharma, amelenodor (NX-13) / Landos Biopharma
Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_691;
Results NX-13, a novel NLRX1 agonist, resulted in regulation of cellular metabolism: activation of mitochondrial genes such as mt - nd3 & odgh , and concomitant down-regulation of glucose uptake by murine T cells (Fig1A)...LABP-69 also reduced superoxide levels in BMDM...J Immunol 203(12) 3 Tubau-Juni et al. J Immunol 206(Supp)